Surgery – Truss – Pad
Patent
1993-08-31
1997-01-07
Rosenbaum, C. Fred
Surgery
Truss
Pad
128659, 128898, A61B 600
Patent
active
055906567
ABSTRACT:
Broadly, the present invention is directed to a method for the detection and differentiation of neoplastic tissue in a patient suspected of having neoplastic tissue. The method includes the administration of a radiolabeled somatostatin congener to the patient and accessing the patient with a radiation detection probe for determining tissue exhibiting elevated levels of radiation, viz., neoplastic tissue. However, before subjecting the patient to such administration, an initial determination preferably is made as to whether the radiolabeled somatostatin congener will bind to the tumor site, i.e., whether somatostatin receptors are associated with the neoplastic tissue. This is conveniently done with a wide variety of endocrine tumors, which release peptides or hormones, referred to as "biochemical markers. " In order to make this determination, initially a biochemical marker-inhibiting dose of unlabeled somatostatin congener is administered to the patient. The biochemical marker associated with the neoplastic tissue then is monitored to determine whether the administered somatostatin congener reduces the presence of the marker in the patient. If the monitored presence of the marker was reduced, then the surgeon can be confident that the neoplastic tissue or tumor contains receptors to which the somatostatin will bind. Thus, the administration of radiolabeled somatostatin congener is appropriate for such patient. If the biochemical marker associated with the neoplastic tissue is not appropriately reduced following the administration of the unlabeled somatostatin congener, then the neoplastic tissue may not be determinable by the use of radiolabeled somatostatin congener and alternative modalities of treatment should be considered, such as the use of radiolabeled antibodies as proposed in U.S. Pat. No. 4,782,840. If the tumor is of a type that does not release a biochemical marker, the presence of somatostatin receptors can be confirmed by other means, such as pathology, immunohistochemistry, radioreceptor assay, or such other means as will be apparent to those skilled in the art.
REFERENCES:
patent: 4782840 (1988-11-01), Martin, Jr. et al.
patent: 4932412 (1990-06-01), Goldenberg
patent: 5094837 (1992-03-01), Bis
patent: 5225180 (1993-07-01), Dean et al.
Merck Index, 10th Edition, p. 1246 (1983).
Bakker et al. "Receptor Scintography with Radio-Iodinated Somatustatin Analog" Journal of Nuclear Medicine, vol. 31, #9 (Sep. 1990).
Lamberts et al. "Somatostatin Receptor Imaging" Journal of Steroid Biochem & Molecular Biology, vol. #37, #6 pp. 1079-1082 (1990).
Lamberts et al. "The Role of Somatostatin" Endocrine Reviews, vol. 12, #4, (1991).
Harris, "Future Medical Prospects for Sandostatin" Metabolism, vol. 39, #9, suppl 2 (Sep. 1990) pp. 180-185.
O'Dorisio et al. "Somatostatin and Somatostatin-like Peptides: Clinical Researchand Clinical Applications" Advances in Endocrinology and Metabolism, vol. 1, Mosha Year Book, 1990.
O'Dorisio et al., "Somatostatin and Somatostatin-like Peptides: Clinical Research and Clinical Application", Advances in Endocrinology and Metabolism, vol. 1, pp. 175-230, Mazzaferri et al., eds.
O'Dorisio et al., "Rationale for Somatostatin Therapy and its Clinical Application as the Congener, Octreotide Acetate", Endocrine Cancer, Mazzaferri et al., eds.
Harris, "Future Medical Prospects for Sandostatin, Metabolism", vol. 39, No. 9, Suppl. 2 (Sep.) 1990: pp. 180-185.
Lamberts et al., "Treatment with Sandostatin and In Vivo Localization of Tumors with Radiolabeled Somatostatin Analogs", Id at pp. 152-155.
Bakker et al., "Receptor Scintigraphy with a Radioiodinated Somatostatin Analog: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals", J. Nucl. Med, 1990, 31: 1501-1509.
Lamberts et al., "Somatostatin Receptor Imagin In Vivo Locatization of Tumors with a Radiolabeled Somatostatin Analog", J. Steroid Biochem, Molec. Biol., vol. 37, No. 6, pp. 1079-1082 (1990).
Reubi, et al., "In Vitro and In Vivo Detection of Somatostating receptors in Phenochromocytomas and Paragangliomas", J. Clin. Endocrinol. Metab., vol. 74, pp. 1082-1089 (1992).
Krenning et al., "Somatostatin Receptor Imaging of Endocrine Gastrointestinal Tumors", Schwiez med. Wschr., 1992, 122: 634-637.
Reubi et al., "Somatostatin Receptor Incidence and Distribution in Breast Cancer Using Receptor Autoradiography: Relationship to EGF Receptors", Int. J. Cancer, 46, 416-420 (1990).
Pantev et al., "Evaluation of Somatostatin Receptors in Human Cancer", Wien Klin Wochenschr, (1991) 103/21, 649-653.
Lemaire et al., "Disposition of Sandostatin, A New Synthetic Somatostatin Analogue, in Rats", Drug Metabolism and Dispotion, vol. 17, No. 6, pp. 699-703 (1989).
Kwekkeboom et al., "Radiodinated Somatostatin Analog Scintigraphy in Small-Cell Lung Cancer", J. Nucl. Med. 1991, 32: 1845-1848.
Krenning, et al., "Somatostatin Receptor Scintigraphy with Indium-111 DTPA-D-phe-10ctreotide in Man: Metabolism, Dosimetry and Comparison with iodine-123-Tyr-3-Octreotide", J. Nucl. Med. 1992, 33: 652-658.
Lamberts et al., "The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors", Endocrine Reviews, vol. 12, No. 4, pp. 450-482 (1991).
Battershill et al., "Octreotide: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Conditions Associated with Excess Peptide Secretion" Drugs, 38 (5), 658-702 (1989).
Katz, et al. "Octreotide, A New Somatostatin Analogue", Clinical Pharmacy, vol. 8, Apr. 1989, pp. 255-273.
Lamberts, "A Guide to the Clinical Use of the Somatostatin Analogue SMS 201-995 (Sandostatin)", Acta Endocrinolgica (Copenh), 1987, Suppl. 286, pp. 54-66.
Evers et al., "Somatostatin and Analogues in the Treatment of Cancer", Annals of Surgery, Mar. 91 213(3), pp. 190-198.
Foekens et al., "Prognostic Value of Receptors for Insulin-like Growth Factor 1", Somatostatin and Epidermal Growth Factor in Human Breast Cancer, Cancer Res., 1989; 49:7002-7005.
Moody et al., "Regulation of the Release of Bombesin-like Peptides from Lung Tumors", Regul. Peptides, 1987; 19: 128-132.
O'Dorisio, et al., "Role of Peptide Radioimmunoassay in Understanding Peptide-Peptide Interactions and Clinical Expression of Gastroenteropancreatic Endocrine Tumors", The American Journal of Medicine, vol. 82 (suppl. 5B), pp. 60-67 (1987).
Reichlin, "Editorial" Clinical Application of Somatostatin Receptor Imaging, Journal of Clinical Endocrinology and Metabolism, vol. 71, No. 3, pp. 564-565 (1990).
Patel, "Somatostatin-Receptor Imaging for the Detection of Tumors", The New England Journal of Medicine, vol. 323, No. 18, pp. 1274-1276 (1990).
Krenning, et al., "Localisation for Endocrine-Related Turmors with Radioiodinated Analogue of Somatostatin", The Lancet, pp. 242-244, Feb. 4, 1989.
Schally, "Oncological Application of Somatostatin Analogues" Cancer Research 48, 6977-6985, Dec. 15, 1988.
Lamberts, et al., "Parallet in Vivo and in Vitro Detection of Functional Somatostatin Receptors in Human Endocrine Pancreatic Tumors: Consequences with Regard to Diagnosis, Localization, and Therapy", Journal of Elinical Endocrinology and Metabolism, vol. 71, No. 3, pp. 566-574.
Malarkey, et al., "Responses of GH-and TSH-Secreting Pituitary Adenoma to a Somatostatin Analogue (SMS 201-995): Evidence that GH and TSH Coexist in the Same Cell and Secretroy Granules", Neuroendocrinology 1989; 49: 267-274.
Kvols, et al., "Treatment of the Malignant Carcinoid Syndrome, Evaluation of Long-Acting Somatostatin Analogue", The New England Journal of Medicine, vol. 315, No. 11, pp. 663-666 (1986).
Lee, et al., "Effects of Epidermal Growth Factor and Analogues of Luteinizing Hormone-Releasing Hormone and Somatostatin on Physphorylation and Dephosphorylation of Tyrosine Residues of Specific Protein Substates in Various Tumors", Proc. Natl. Acad. Sci, USA, vol. 88, pp. 1656-1660 (1991).
Beck-Peccoz, et al., "Treatment of Inappropriate Secretion of Thyrotropin with Somatostatin Analog SMS 201-995", Hormone Res. 29: 121-123 (1988).
Lamberts, "Somatostatin Analogs in the Management of Gastrointesti
Martin, Jr. Edward W.
O'Dorisio M. Sue
O'Dorisio Thomas M.
Woltering Eugene A.
Rosenbaum C. Fred
Smith Chalin
The Ohio State University Research Foundation
LandOfFree
Application of peptide/cell receptor kinetics utilizing radiolab does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Application of peptide/cell receptor kinetics utilizing radiolab, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Application of peptide/cell receptor kinetics utilizing radiolab will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1757349